- Top monthly contributors across multiple themes include – Schrodinger up 22.6% (Bionformatics), JMDC 20.7% (Healthcare Analytics), Omeros Corp 20.0% (Neuroscience), Xenon Pharma 16.9% (Neuroscience), Cochlear Ltd 19.2% (Medical Devices), Beam Therapeutics 13.2% (Gene Sequencing), Alnylam Pharma 14.7% (Biotech) and iRhythm 3.4% (Trackers). [1]
- WELL’s returns are driven by Medical Device holdings (27.3% weight), Biotech (24.3%), Genome Sequencing (16.1%), Neuroscience (9.9%) & Telemedicine (6.9%). [1]
- Neuroscience was the best Subtheme performer in February, contributing 4.5% gains to WELL. [2]
- Healthcare Analytics jumped 3.6% and Medical Devices gained 2.6%. [2]
- Subthemes continued wide dispersion of returns in early 2022 - Genome Sequencing losing 8.3% and Healthcare Trackers 25.1%. [1]
- Holdings are global – US 68.9%, Japan 7.9%, China 6.1% and Europe 13.9%. [1]
Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Please note that all performance figures are showing net data.
Macro Outlook
Recent deals by Oracle, Google and Microsoft reflect the growth of Cloud Computing in the medical space – and how Hospitals are fully embracing Telehealth, Analytics and Digitalization.
Big Tech increasingly active across the Healthcare Innovation space. We expect more Big Tech deals - following the latest Oracle almost $30bn Cerner digital data deal (electronic medical records). [3]
Reflects that Healthcare represents almost 20% of the US GDP – a giant untapped market for Tech deals. Given Healthcare’s size, Big Tech can easily make acquisitions in this space without any concern for US anti-trust rules blocking their deals. [4]
Microsoft’s $26bn Nuance Communications acquisition & Google Cloud’s digitalization deal with one of the largest US hospital groups (HCA Healthcare 2000+ locations) – highlights the increasing use of Cloud and Digital Tech to push Healthcare into the 21st century. [5]
Top Subtheme Contributions
|
|
Contribution to Return
|
|
Sub-Themes
|
YTD
|
February
|
|
Telemedicine
|
-15.3%
|
-1.3%
|
|
Genome Sequencing
|
-29.7%
|
-8.3%
|
|
Medical Devices
|
-9.7%
|
2.6%
|
|
Neuroscience
|
-6.3%
|
4.5%
|
|
Bioinformatics
|
-14.9%
|
0.9%
|
|
Biological Engineering
|
-13.2%
|
-1.6%
|
|
Healthcare Analytics
|
-18.8%
|
3.6%
|
|
Robotics
|
-11.0%
|
-0.3%
|
|
Healthcare Trackers
|
-23.0%
|
-25.1%
|
Past performance is no guarantee of future performance. Please note that all performance figures are showing net data.
Source: INDXX. Data as of 28.02.2022
|
Company Name
|
Sub-Themes
|
February
(Contribution to Return)
|
|
SCHRODINGER INC
|
Bioinformatics |
5.65%
|
|
JMDC INC
|
Healthcare Analytics |
4.15%
|
|
OMEROS CORP
|
Neuroscience
|
2.00%
|
|
IRHYTHM TECHNOLOGIES INC
|
Healthcare Trackers |
1.78%
|
|
XENON PHARMACEUTICALS INC
|
Neuroscience |
1.69%
|
|
MEDPEER INC
|
Telemedicine |
1.43%
|
|
NEUROCRINE BIOSCIENCES INC
|
Neuroscience |
1.37%
|
|
ACADIA PHARMACEUTICALS
|
Neuroscience |
1.30%
|
|
MEDICAL DATA VISION CO LTD
|
Healthcare Analytics |
1.15%
|
|
INTUITIVE SURGICAL INC
|
Robotics |
1.08%
|
|
|
1M
|
3M
|
6M
|
YTD
|
12M
|
2Y
|
3Y
|
SI
|
|
HANS-GINS Indxx Healthcare Megatrend
|
-0.85%
|
-14.30%
|
-25.77%
|
-15.34%
|
-21.37%
|
6.53%
|
NA
|
12.12%
|
|
Indxx Global NextGen Healthcare Index (NTR)
|
-0.83%
|
-14.18%
|
-25.72%
|
-15.25%
|
-21.25%
|
7.35%
|
13.42%
|
13.80%
|
Past performance for the index is in USD. Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Investors should read the prospectus of the Issuer (“Prospectus”) before investing and should refer to the section of the Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in this product. Source: Bloomberg / HANetf. Data as of 28/02/2022. Please note that all performance figures are showing net data.
Learn more about our Equal Weight ETF
Download the PDF